Navigation Links
Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
Date:1/16/2012

SCOTTSDALE, Ariz., Jan. 16, 2012 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant® Therapy System, announced today that Scott Brooks has joined the company in the newly created position of Chief Operating Officer. Scott is responsible for helping scale the organization's capabilities to support increased market penetration and broadened reimbursement.

(Logo: http://photos.prnewswire.com/prnh/20120109/LA31405LOGO)

Most recently Scott was President of sales, marketing and customer service at BSN Medical located in Charlotte, NC. He led a team of 190 people in the US and Canada. Prior to that, Scott was the VP of Sales and National Accounts at Kinetic Concepts Inc. (KCI), the marketer of the wound VAC. At KCI he managed a team of sales and national accounts professionals who sold advanced wound care, critical care, and bariatric care devices in the US to hospitals, nursing homes, and homecare. Scott served on the KCI management team as the company emerged into a global leader. His experience includes successful leadership positions with The Hill-Rom Company, Kimberly Clark Health Care, and Covidien.

"Scott is a mission focused, strategic, and process minded leader with experience scaling an organization," said Virginia Rybski, President and CEO of Regenesis. "We look forward to his contributions in building upon our performance based culture."

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

About the Provant® Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: Regenesis Biomedical, Inc.
Scott Robey, Vice President Marketing
www.regenesisbio.com
480-970-4970 phone


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
2. Pioneering US/Scottish Alliance for Life Science and Clinical Informatics
3. Scotland Announces Goal to Double Life Sciences Contribution to Scottish Economy by 2020 at BIO
4. Scott Garrett Joins Water Street Healthcare Partners
5. TGen and Scottsdale Healthcare researchers discover microRNA role in brain metastasis
6. Scott & White Healthcare President and CEO Alfred B. Knight, M.D. to Retire in 2011, Will Lead Foundation
7. Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing
8. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
9. SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business
10. United States Recognizes Leading Scottish Scientist for Disease Research
11. MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Myrtle Beach, SC (PRWEB) , ... April 26, ... ... for the mind, has teamed up with NASA to showcase the future of ... NASA’s Space Launch System (SLS) rocket and Orion spacecraft and includes a guest ...
(Date:4/26/2017)... RESTON, Va. (PRWEB) , ... April 26, 2017 ... ... to make headlines and drive high-level conversations among healthcare industry stakeholders, the discussion ... Healthcare Environment – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted ...
(Date:4/25/2017)... PROVIDENCE, R.I. , April 25, 2017 /PRNewswire/ ... EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology ... in autoimmune disease and allergy. Tregitopes, ... discovered in human immunoglobulin by EpiVax CEO ... Martin. Similar to intravenous immunoglobulin G, an autoimmune ...
(Date:4/24/2017)... April 24, 2017  Dante Labs announced today the offer ... 850 (ca. $900). While American individuals have been able to ... Europeans can access WGS below EUR 1,000. The ... leveraging genetic information to make informed decisions about disease monitoring, ... ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):